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Abstract: INTRODUCTION Bromelain-based Enzymatic Debridement has been introduced as an addi-
tional concept to the burn surgeon’s armamentarium and is best indicated for mid-to deep dermal burns
with mixed patterns. Increasing evidence has been published focusing on special regions and settings as
well as on limitations of Enzymatic Debridement to improve patient care. To better guide Enzymatic
Debridement in view of the increasing experience, there is a need to update the formerly published con-
sensus guidelines with user-orientated recommendations, which were last produced in 2017. METHODS
A multi-professional expert panel of plastic surgeons and burn care specialists from twelve European
centers was convened, to assist in developing current recommendations for best practices with use of
Enzymatic Debridement. Consensus statements were based on peer-reviewed publications and clinical
relevance, and topics for re-evaluation and refinement were derived from the formerly published European
guidelines. For consensus agreement, the methodology employed was an agreement algorithm based on a
modification of the Willy and Stellar method. For this study on Enzymatic Debridement, consensus was
considered when there was at least 80 % agreement to each statement. RESULTS The updated consensus
guidelines from 2019 refer to the clinical experience and practice patterns of 1232 summarized patient
cases treated by the panelists with ED in Europe (2017: 500 cases), reflecting the impact of the published
recommendations. Forty-three statements were formulated, addressing the following topics: indications,
pain management and anesthesia, large surface treatment, timing of application for various indications,
preparation and application, post-interventional wound management, skin grafting, outcome, scar and
revision management, cost-effectiveness, patient´s perspective, logistic aspects and training strategies.
The degree of consensus was remarkably high, with consensus in 42 out of 43 statements (97.7%). A clas-
sification with regard to timing of application for Enzymatic Debridement was introduced, discriminating
immediate/very early (฀12 h), early (12-72 h) or delayed (>72 h) treatment. All further recommendations
are addressed in the publication. CONCLUSIONS The updated guidelines in this publication represent
further refinement of the recommended indication, application and post-interventional management for
the use of ED. The published statements contain detailed, user-orientated recommendations aiming to
align current and future users and prevent pitfalls, e.g. for the successful implementation of ED in further
countries like the USA. The significance of this work is reflected by the magnitude of patient experience
behind it, larger than the total number of patients treated in all published ED clinical trials.
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hDivisionofPlastic,Aesthetic and Reconstructive Surgery, Department of Surgery, MedicalUniversityof Graz, Graz, Austria
iDepartment of Plastic and Reconstructive Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, "Carol Davila"
University of Medicine and Pharmacy, Bucharest, Romania
j Burn Unit, Hospital Universitario La Paz, Madrid, Spain
kDivision of Plastic Surgery and Hand Surgery, Burn Center, University Hospital Zurich, Zurich, Switzerland
l Burn Center with Plastic Surgery, Unfallkrankenhaus Berlin, Berlin, Germany
a b s t r a c t
Introduction: Bromelain-based Enzymatic Debridement has been introduced as an additional
concept to the burn surgeon's armamentarium and is best indicated for mid-to deep dermal
burns with mixed patterns. Increasing evidence has been published focusing on special
regions and settings as well as on limitations of Enzymatic Debridement to improve patient
care. To better guide Enzymatic Debridement in view of the increasing experience, there is a
need to update the formerly published consensus guidelines with user-orientated
recommendations, which were last produced in 2017.
Methods: A multi-professional expert panel of plastic surgeons and burn care specialists from
twelve European centers was convened, to assist in developing current recommendations for
best practices with use of Enzymatic Debridement. Consensus statements were based on
peer-reviewed publications and clinical relevance, and topics for re-evaluation and
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refinement were derived from the formerly published European guidelines. For consensus
agreement, the methodology employed was an agreement algorithm based on a
modification of the Willy and Stellar method. For this study on Enzymatic Debridement,
consensus was considered when there was at least 80 % agreement to each statement.
Results: The updated consensus guidelines from 2019 refer to the clinical experience and
practice patterns of 1232 summarized patient cases treated by the panelists with ED in
Europe (2017: 500 cases), reflecting the impact of the published recommendations. Forty-
three statements were formulated, addressing the following topics: indications, pain
management and anesthesia, large surface treatment, timing of application for various
indications, preparation and application, post-interventional wound management, skin
grafting, outcome, scar and revision management, cost-effectiveness, patients perspective,
logistic aspects and training strategies. The degree of consensus was remarkably high, with
consensus in 42 out of 43 statements (97.7%). A classification with regard to timing of
application for Enzymatic Debridement was introduced, discriminating immediate/very
early (12 h), early (1272 h) or delayed (>72 h) treatment. All further recommendations are
addressed in the publication.
Conclusions: The updated guidelines in this publication represent further refinement of the
recommended indication, application and post-interventional management for the use of
ED. The published statements contain detailed, user-orientated recommendations aiming to
align current and future users and prevent pitfalls, e.g. for the successful implementation of
ED in further countries like the USA. The significance of this work is reflected by the
magnitude of patient experience behind it, larger than the total number of patients treated in
all published ED clinical trials.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Since its approval in Europe in 2013, Bromelain-based
Enzymatic Debridement with Nexobrid1 has become a reliable
and useful alternative to operative eschar removal, which has
been found to be most beneficial in mid- to deep dermal burns
and mixed depth patterns. There is a continuously growing
number of burn centers successfully treating an increasing
number of burn patients, with Enzymatic Debridement with
beneficial outcome. Several studies have addressed the
selective approach and advantages of Enzymatic Debride-
ment, which may reduce procedural blood loss, the need for
autologous skin grafting and the number of wounds with
further surgical excision by preserving more viable dermis
compared to the standard of care (SOC) [1]. Additionally,
Enzymatic Debridement has the advantage of reducing the
rate of burn wound infection and the length of hospital stay
compared to SOC [2].
In a first European consensus expert panel meeting on
Enzymatic Debridement with Nexobrid1 in 2017, the experi-
ence of treating more than 500 adult and pediatric patients was
summarized by addressing relevant issues as a preliminary
guideline with user-oriented recommendations for a success-
ful implementation [3]. Sixty-eight consensus statements
were provided, with a remarkably high degree of 88.2 %
consensus for all statements [3].
Within the last 5 years, increasing evidence on Enzymatic
Debridement has been published with a focus on special
regions and settings. Likewise, its limitations have been
discussed in order to increase success rates and acceptability
in view of improved patient care and outcome.
Hot topics on enzymatic debridement that have been
addressed were the special issues of treating burned hands [4
9] as well as burns to the face [10] and genitals [11], with most
published studies and patients on hand burns.
Immediate application of Enzymatic Debridement in
circumferential burns to the extremity was investigated by
Fischer et al. who showed its effectiveness and safety for the
prevention of burn-induced compartment syndrome in clini-
cal practice, reducing the need and burden of surgical
escharotomy [12].
Another important issue, the “quality” of enzymatic
debridement was examined taking biopsies harvested from
partial thickness burn wounds, before and after enzymatic
treatment, with additional histological assessment [13]. The
authors demonstrated that partially damaged dermis was
always spared by enzymatic debridement, but showed some
"homogenization" characteristics and only few vital skin
adnexal structures. They concluded that this dermal portion
could desiccate if mismanaged as a trigger for neo-eschar or
the well-known pseudo-eschar after enzymatic debridement
with Nexobrid1 [13].
As a consequence of successful clinical application, cost-
efficacy analyses and associated implementation strategies
for Nexobrid1 based on national models and calculations due
to different reimbursement modalities have become another
relevant focus of enzymatic debridement in burns [14,15]. The
treatment of diabetic foot burns has been demonstrated as a
limitation due to deepening and unfavorable outcome in a case
series [16]. Delayed application after the thermal injury was
addressed in view of logistical reasons and patient stability.
With special burn wound preparations prior to Enzymatic
Debridement, delayed application has been demonstrated as
783
feasible [17]. Some case reports addressed fractional and
delayed Enzymatic Debridement in large burn surfaces [18]
and the relevance of coagulation abnormalities [19] — issues
that all should be newly reevaluated in view of this new
modality.
In order to update the role and advantages of Bromelain-
based Enzymatic Debridement since the first European
consensus meeting on Enzymatic Debridement in 2017, a
2nd European consensus meeting was scheduled in order to re-
evaluate the former consensus statements and focus on new
relevant issues.
2. Methods
During the first European consensus meeting in 2017 [3],
consensus statements on Enzymatic Debridement for eschar
removal in burns were formulated by a multistep process. In
brief, a systematic literature review of the recent literature
(20132018) including the publication of the first European
consensus meeting was used as a basis for pre-formulated
statements by CH, UK and BZ addressing all relevant topics.
These statements were sent to all panelists in advance and
were the basis for panel discussions. Due to the limited
number of publications and the novelty of the treatment
modality of enzymatic debridement in burns, systematic
consensus measures (e.g., Delphi method) were not applied,
and a modified consensus process was implemented.
2.1. Panelists
European expert panelists were selected by the first and senior
author (CH and UK) based on the following criteria: clinical
experience and prior publications on Enzymatic Debridement
with Nexobrid1, general expertise and reputation in burn
treatment, and role as key opinion leader. Selection of
panelists was limited to Europe due to the medical approval
of Nexobrid1 and the aim to establish a 2nd European
consensus. The included diversity of experience and practice
patterns of 1232 summarized patient cases in Enzymatic
Debridement with Nexobrid1 from a variety of European
geographic locations provided a broad spectrum and high level
of expertise in the panel. Panelists who participated came from
ten European countries: Austria, Belgium, Germany, Italy,
Norway, Poland, Romania, Spain, Switzerland and United
Kingdom, and encompassed plastic surgeons, burn surgeons
and burn care specialists for a multi-professional panel. Every
participating center had one vote per statement (12 votes
altogether), regardless of the number of participants present
from the center.
2.2. Process and meeting
Prior to the face-to-face meeting (which was scheduled in
March 2019 in Frankfurt, Germany), all panelists were provided
with 75 possible, pre-formulated consensus statements on
enzymatic debridement for eschar removal in burns based on
peer-reviewed publications and clinical relevance, suggested
topics by the invited panelists, and topics for re-evaluation
from the first European consensus meeting [3] for further
discussion and adaption. Statements were either re-included
if they were not consented unanimously in 2017 or if they
underwent re-consideration due to new experience and
evidence.
The statements included the following topics: indications,
pain management and anesthesia, large surface indication,
timing of application for various indications, preparation and
application, post-interventional wound management, skin
grafting, outcome and scar and revision management, cost-
efficacy, patients perspective, logistic aspects and training
strategies. Due to the process, some of the topics have been
modified during the panel discussion.
The consensus workshop was divided into two major
sections: The first section included the presentation of a
systematic review on enzymatic debridement for eschar
removal in burns in order to synchronize the level of evidence
for the years 20132018 between the panelists. The next major
section consisted of discussion of all 75 pre-formulated
statements; personal experience was shared by the panel
and changes in wording, merging or deletion of statements
were addressed and finally consented. The panelists, with one
vote per center, were asked to mark agreement or disagree-
ment with each consensus statement at the end of the debate.
All panelists were asked to reflect the consensus state-
ments list and results by proof-reading of the final consensus
manuscript and a follow-up discussion via email. Panelists
were encouraged to make comments and suggestions for
changes to the manuscript. The final version of the manuscript
was accepted and agreed for submission by all participants.
2.3. Consensus agreement
Consensus agreement was achieved with reference to the first
European consensus meeting [3]. In brief, the methodology
employed was an agreement algorithm based on a modifica-
tion of the Willy and Stellar method [20]. For this study on
Enzymatic Debridement, consensus was considered when
there was at least 80 percent agreement, (i.e. at least 10 of 12
participants), to each statement. The results are summarized
in Tables 113 with the first column showing each statements
serial number (143), the second column representing each
statement, the third column displays the tally and percentage
of “yes/no” votes and the fourth column summarizes whether
the statement achieved consensus based upon the above
mentioned criteria.
2.4. Standard of care (SOC)
Throughout the whole consensus process, surgical excision
with tangential knives and/or hydro surgery were regarded as
surgical standard of care (SOC) and if applicable compared to
Enzymatic Debridement. The panelists agreed that everything
that is not exclusively defined for Enzymatic Debridement,
shall follow the SOC for burn eschar removal.
3. Results
The following topics and consensus statements are based on
the summarized experience of treating 1232 patients since
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Table 2 – Consensus statements and agreement on application of Enzymatic Debridement special regions.
No. Consensus statement Yes No Consensus
12 ED treatment of burns on the palm or sole might be indicated in selected
patients but with specific mechanical treatment
12/12 (10 %) 0/12 (0%) Yes
13 ED is highly recommended for facial burns. 12/12 (100%) 0/12 (0%) Yes
14 Orifices of the face require special protection measures to prevent from
contact with product.
12/12 (100%) 0/12 (0%) Yes
15 Ophthalmological exam after facial burns is recommended prior to and
after ED treatment.
12/12 (100%) 0/12 (0%) Yes
16 ED is recommended for perineal and genital burns. 12/12 (100%) 0/12 (0%) Yes
Table 1 – Consensus statements and agreement on indications of enzymatic debridement.
No. Consensus statement Yes No Consensus
1 Classifications with regard to timing of application for ED are “immediate/
very early” (12 h), early (1272 h) or delayed (>72 h).
12/12 (100%) 0/12 (0%) Yes
2 ED might be less effective in scald injuries. 12/12 (100%) 0/12 (0%) Yes
3 There is not enough evidence to recommend ED for chemical burns. 12/12 (100%) 0/12 (0%) Yes
4 Outpatient treatment/ED as a day case can be performed after careful
patient selection in minor burns in experienced burn centers.
9/12 (75%) 3/12 (25%) No
5 Repeated application of ED can only be recommended in exceptional cases. 12/12 (100%) 0/12 (0%) Yes
6 ED is best indicated for mid-to deep dermal burns with mixed patterns. 12/12 (100%) 0/12 (0%) Yes
7 ED can be applied in full thickness burns. 12/12 (100%) 0/12 (0%) Yes
8 Application of ED as early as possible during admission can prevent burn
related compartment syndrome in circumferential extremity burns.
12/12 (100%) 0/12 (0%) Yes
9 ED applied as early as possible during admission might prevent develop-
ment of burn induced compartment syndrome in extensive trunk burns.
12/12 (100%) 0/12 (0%) Yes
10 ED cannot replace surgical release for extended trunk burns in case of
established respiratory compromise.
12/12 (100%) 0/12 (0%) Yes
11 ED is not recommended in the extremity in case of established compart-
ment syndrome and high voltage injury.
12/12 (100%) 0/12 (0%) Yes
Table 3 – Consensus statements and agreement on imaging prior/after Enzymatic Debridement.
No. Consensus statement Yes No Consensus
17 LDI is a helpful tool for identification of regions that undergo ED. 12/12 (100%) 0/12 (0%) Yes
18 At the moment there is no evidence to support LDI after ED. 11/12 (91.7%) 1/12 (8.3%) Yes
Table 4 – Consensus statements and agreement on pain management and anesthesia for Enzymatic Debridement.
No. Consensus statement Yes No Consensus
19 Regional anesthesia is recommended for ED of the isolated (upper/lower)
burnt extremity.
12/12 (100%) 0/12 (0%) Yes
20 Local anesthesia for ED is useful in minor burns. 12/12 (100%) 0/12 (0%) Yes
Table 6 – Consensus statement and agreement on timing of Enzymatic Debridement application.
No. Consensus statement Yes No Consensus
23 Late application (>72 h from injury) is possible in selected wounds after
appropriate prolonged presoaking
12/12 (100%) 0/12 (0%) Yes
Table 5 – Consensus statements and agreement on Enzymatic Debridement for large surface treatment.
No. Consensus statement Yes No Consensus
21 Sequential ED procedures for larger TBSA are possible with up to 15% TBSA per
session.
12/12 (100%) 0/12 (0%) Yes
22 ED of more than 15% BSA/session requires adequate monitoring and
hemodynamic support and is considered as an off-label use.
12/12 (100%) 0/12 (0%) Yes
785
Table 7 – Consensus statements and agreement on preparation and application of Enzymatic Debridement.
No. Consensus statement Yes No Consensus
24 Coagulopathy has to be treated prior to ED. 12/12 (100%) 0/12 (0%) Yes
25 Hydrogel dressings can be used as an effective moisturizer to for dry eschar
to improve pre-soaking.
12/12 (100%) 0/12 (0%) Yes
26 Pre-Soaking can be scheduled overnight to synchronize the ED application
with the day shift team.
12/12 (100%) 0/12 (0%) Yes
27 Pretreatment with silver sulfadiazine or betadine should be avoided 12/12 (100%) 0/12 (0%) Yes
28 Persistent dry eschar after pre-soaking requires superficial surgical
debridement prior to ED.
12/12 (100%) 0/12 (0%) Yes
29 Shortening of the application time of the product <4 h cannot be
recommended.
11/12 (91.7%) 1/12 (8.3%) Yes
Table 8 – Consensus statements and agreement on post-interventional wound management after Enzymatic Debridement.
No. Consensus statement Yes No Consensus
30 Immediate post-ED wound bed color, bleeding patterns and 3D morphology
should be assessed by an experienced burn surgeon.
12/12 (100%) 0/12 (0%) Yes
31 A management plan with regard to further treatment modalities should be
directly defined after ED by an experienced burn surgeon.
12/12 (100%) 0/12 (0%) Yes
32 Membrane dressings and allografts can be applied after wet-to-dry phase in
wounds that are expected to heal without autografting.
12/12 (100%) 0/12 (0%) Yes
33 Allografts can be applied temporarily in wounds that are not expected to heal
spontaneously after ED prior to autografting.
12/12 (100%) 0/12 (0%) Yes
34 Indication for administration of antibiotics in the context is equivalent to
surgical eschar removal.
12/12 (100%) 0/12 (0%) Yes
Table 9 – Consensus statements and agreement on autologous skin transplantation after Enzymatic Debridement.
No. Consensus statement Yes No Consensus
35 In case of full thickness burns after ED, autologous skin grafting should be
delayed for at least 2 days.
12/12 (100%) 0/12 (0%) Yes
36 Deep dermal burn wounds may benefit from early autografting. 12/12 (100%) 0/12 (0%) Yes
37 Autologous skin grafting should be considered after 21 days if there is no
significant progress in epithelization.
11/12 (91.7%) 1/12 (8.3%) Yes
Table 10 – Consensus statements and agreement on outcome, scars and revision management after Enzymatic
Debridement.
No. Consensus statement Yes No Consensus
38 Scar treatment and prevention of hypertrophic scars is performed according to
established standard protocols in burn care (Compression garments, silicon and abstention from
UV-radiation).
12/12 (100%) 0/12 (0%) Yes
39 Prolonged conservative treatment after ED may result in unstable scarring with
intensive wound care, and regular reconsideration should be given for autografting.
12/12 (100%) 0/12 (0%) Yes
Table 12 – Consensus statement and agreement on the patients perspective after Enzymatic Debridement.
No. Consensus statement Yes No Consensus
41 Data on the patients experience on ED are rare and future research on
patient experience is needed.
12/12 (100%) 0/12 (0%) Yes
Table 11 – Consensus statement and agreement on cost-effectiveness of Enzymatic Debridement.
No. Consensus statement Yes No Consensus
40 ED may help to reduce usage of resources (blood products, surgery, OR
room capacity, human resources)
12/12 (100%) 0/12 (0%) Yes
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2013 and in accordance with the recent literature. The
statements were agreed upon during the 2nd European
consensus meeting in March 2019 and finally included 43
statements of the 75 initially submitted to the panelists. The
final list of recommendations in this paper is the result of
modification, merging, and deletion of the initial statements
and adaption of new topics during the panel discussion.
3.1. Consensus statements on indications
1 Classifications with regard to timing of application for ED
are immediate/ very early“(12 h), “early” (1272 h) or
“delayed” (>72 h). [12/12]
A definition of the different timings of Enzymatic Debride-
ment is essential for this relatively new technique to provide
the strategies, concepts and special measurements behind, to
compare results and apply the product in view of the
manufacturers guidelines or willfully as an off-label
indication:
“Very early/ immediate” (within 12 h after trauma)
describes enzymatic debridement during the admission
process, in which most of the burn wounds are still moist
and do not require pre-soaking. It also includes patients after
admission with initiated resuscitation phase, who due to
increasing edema benefit from enzymatic debridement as an
alternative strategy for surgical escharotomy to prevent burn-
induced compartment syndrome.
“Early” (between 12 and 72 h after trauma) enzymatic
debridement is regarded as the gold standard in order to take
advantage of the primary benefits of enzymatic debridement.
It should be applied according to the manufacturers recom-
mendations or according to preceding publications, e.g. the 1st
European consensus guidelines [3].
“Delayed” (more than 72 h after trauma) enzymatic
debridement is regarded as feasible, but may require addi-
tional pretreatment, e.g. mechanical removal of crusts or dry
debris as well as prolonged pretreatment, e.g. pre-soaking.
Dryness is a common and classic feature of full thickness
burns, because contact with hot surfaces and exposure to
flames are a common mechanism of injury. If delay due to
scheduled secondary referral is an issue and full thickness
burns are expected, initiation of presoaking by wet dressings
with antiseptic solution on burned skin before transfer may
help avoid this desiccation.
Patients not responding to Enzymatic Debridement should
have their compartment pressures monitored as part of the
protocol with the option of converting to escharotomy in case
of deterioration.
The panel agrees that both more experience and research is
of benefit including more specific classification features of
burns and use of its definition and their related tracks for
enzymatic debridement in daily routine, as pretreatment
differs and may significantly affect the outcome.
2 Enzymatic debridement might be less effective in scald
injuries. [12/12]
Incomplete removal of scalds has been seen after Enzy-
matic Debridement, which may derive from the extent of
depth of the zone of stasis which develops delayed as burn
wound progression, especially in old patients. Due to potential
deepening, Enzymatic Debridement should be applied “de-
layed”, as incomplete removal of scalds has most frequently
occurred after “early” enzymatic debridement. The patho-
physiology of the scald burn per se is regarded as a potential
drawback of the technique in scalds. Stepwise degradation of
the dermal fibers may impede the efficiency of Enzymatic
Debridement. Most scalds occur in children, where Enzymatic
Debridement is still an off-label-use. In children with scald
injuries, the panelists agree that the success of ED and
“delayed” application is higher than in older patients.
3 There is not enough evidence to recommend enzymatic
debridement for chemical burns. [12/12]
Chemical burns are considered to result in dry surfaces,
which hinder Enzymatic Debridement to penetrate the eschar.
Some chemical agents may interfere with or inactivate the
active enzymes. They are difficult to be standardized accord-
ing to agent and concentration. The panelists agree that
individual decisions, depending on type and concentration of
the agent are necessary. One center has experience with 3
cases of sulfuric acid with each receiving 2 applications.
Altogether, 4 centers treating 8 patients have experience with
mixed results with additional application. Currently, there is
no clear evidence that supports use of Enzymatic Debridement
in chemical burns.
4 Outpatient treatment/ED as a day case can be performed
after careful patient selection in minor burns in experi-
enced burn centers. [9/12]
Based on the methodology of this study, no consensus was
achieved for the treatment of minor burns by enzymatic
debridement as ambulatory care. Application of Enzymatic
Debridement in minor burns to the distal extremity, with a
maximum of up to approximately 2% TBSA burns may be an
effective procedure with local or regional anesthesia, and
Table 13 – Consensus statements and agreement on logistic aspects for implementation and training strategies/learning
curve for Enzymatic Debridement.
No. Consensus statement Yes No Consensus
42 ED can be performed in the operating theatre, intensive care unit or regular
ward dependent on the TBSA treated and the anesthesia regimen.
12/12 (100%) 0/12 (0%) Yes
43 ED is a specialist procedure that requires specific training, adaption to
infrastructure as well as multiprofessional involvement.
12/12 (100%) 0/12 (0%) Yes
787
seems to be technically feasible in an outpatient setting.
Ambulatory care in general may have benefits, such as
reduced overall treatment costs and improved quality of life
for some patients. Nevertheless, appropriate aftercare is
necessary to keep the level of quality of burn treatment,
which benefits from special infrastructure and is regarded as
one of the major concerns resulting in “no consensus” without
further evidence.
5 Repeated application of ED can only be recommended in
exceptional cases. [12/12]
Incomplete debridement after Enzymatic Debridement
may derive from technical issues during application or
deepening in cases where Enzymatic Debridement has been
applied too early. Repeated application in cases after deepen-
ing of the burn wound is not recommended. Repeated
application is only recommended in cases where technical
issues are clearly identified as the reason for failure of
Enzymatic Debridement (loss of contact of enzyme, product
leakage, concentration of enzyme etc.), and it is clear that
these patients may still benefit from Enzymatic Debridement
by a re-application.
6 ED is best indicated for mid-to deep dermal burns with
mixed patterns. [12/12]
The surgical excision of post burn necrotic tissue has been
showntoincludehealthy,unburnedtissueuptoanextent,which
correlates with the surgeons experience, concentration and type
of knife. The surgeons ability to accurately excise is expected to
decreaseinmixedpatterns,whereburntareastobeexcisedarein
close proximity to areas which have the potential to heal. A
biopsy guided- study to demonstrate the strength of Enzymatic
Debridement has been published, underlining the ability to
preserve healthy tissue, but altering the dermal morphology and
thus requiring special post-interventional wound management
[13]. The panelists' experience underlines the indication for mid-
to deep dermal burns with mixed patterns, where Enzymatic
Debridement exerts its strength by a selective approach.
7 ED can be applied in full thickness burns. [12/12]
Enzymatic Debridement exerts its strength in mid-to deep
dermal burns with mixed patterns to preserve as much viable
dermis as possible for improved functional outcome.
Its application in full thickness burns can be regarded as a
useful indication, to reduce the time to complete eschar
removal, e.g. in case of lack of operation theatre availability.
This is also the case in technically demanding areas and in
areas where subcutaneous layers are very thin, it may help
preserve functional structures  even if the preservation of
dermis is not the primary aim.
8 Application of ED as early as possible during admission can
prevent burn related compartment syndrome in circum-
ferential extremity burns. [12/12]
Burn-induced compartment syndrome (BICS) is a severe
sequela following circumferential burns of the extremities.
Immediate release of the increasing compartment pressure
has the potential to prevent BICS by incising or removing the
eschar. Surgical escharotomy is regarded as the current gold
standard, but carries the risk of considerable morbidity. If
specific contraindications are respected, Enzymatic Debride-
ment is a safe and effective alternative for the prevention of
BICS after deep circumferential burns at the upper extremity,
thus making operative escharotomy unnecessary in many
cases [6]. Fischer et al. demonstrated the feasibility and safety
of Enzymatic Debridement for the prevention of operative
escharotomy in circumferential deep burns of the distal upper
extremity [12]. It should be applied as early as possible (“very
early”), and should not be delayed by presoaking. The
technique of surgical escharotomy should be kept available
from the point of surgical skills and competence, and the
extremity treated by Enzymatic Debridement to prevent BICS
benefits from close re-evaluation  which does not differ from
surgical escharotomy [6,12]. In an experimental setting,
Enzymatic Debridement was shown to release increasing
compartment pressure within 30 min [21].
The experience of the panelist also includes “very early”
Enzymatic Debridement of the chest and neck to prevent from
restriction and further complications by circular eschar on
airway and breathing. The results of the panelist consistently
include appropriate and effective results.
9 ED applied as early as possible during admission might
prevent development of burn induced compartment
syndrome in extensive trunk burns. [12/12]
Analogous to the effect of very early/immediate application
of Enzymatic Debridement on circumferential burns to the
extremities, there might be a positive effect for trunk burns to
prophylactically release eschar related intra-abdominal pres-
sure or improve thoracic wall excursion to improve resistance
related breathing and ventilation restrictions. Currently, there
is no evidence which has systematically evaluated this issue.
10 ED cannot replace surgical release for extended trunk
burns in case of established respiratory compromise.
[12/12]
In case of acute respiratory failure due to circumferential
trunk burns, surgical escharotomy to release the pressure is
mandatory.
11 ED is not recommended in the extremity in case of
established compartment syndrome and high voltage
injury. [12/12]
Due to a different pathophysiology, the incapability of the
enzyme to dissolve vital fascial structures and the limited
experience with Enzymatic Debridement for this indication, the
panelists do not recommend the technique to release an
established compartment syndrome. In a high voltage injury,
the affected extremity is usually characterized by both a dermal
eschar and deep tissue damage below the fat layer, such as
muscle and fascia, which triggers inflammatory processes of
deep edema with risk of sub-fascial compartment syndrome.
These extremities benefit from surgical fasciotomy. However, ED
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can be used as an adjunctive treatment after surgical decom-
pression for dermal eschar removal.
3.2. Consensus statements on special regions
a. Hand/foot
12 ED treatment of burns on the palm or sole might be
indicated in selected patients but receives specific me-
chanical treatment. [12/12]
The treatment of hands is one of the most frequently
evaluated fields of interest in Enzymatic Debridement in the
last 5 years. Recently, Cordts et al. summarized their
experience with Enzymatic Debridement for hands and the
upper extremity under regionally administered anesthesia
showing that no further surgical intervention was undertaken
in 53.8 % of patients, and the skin-grafted areas could be
reduced by 37.0 % when compared to initial assessment in
patients who underwent further skin grafting. The time from
injury to ED was 24.4 h, and patients were able to start physical
therapy after 2.0 days but suffered from prolonged wound
closure (28.0 days) [4]. In a comparative study between SOC and
Enzymatic Debridement on hands, Schulz et al. demonstrated
that Enzymatic Debridement significantly reduced time to
complete debridement after admission (0.95 day vs 7.750 days;
p < 0.001) and number of treatments needed for complete
debridement (1.05 vs 1.45; p < 0.001). In line with the preceding
results, the number of wounds with autografting was reduced
(15% vs 95%; p = 0.034), as was time to complete healing after
first debridement (23.30 vs 32.00 days; p < 0.001). Scar quality
for the hands and early scar quality after 3 months was nearly
equivalent, with only increased local redness after Enzymatic
Debridement [9]. Krieger et al. evaluated the concept of
Enzymatic Debridement in hand burns in another compara-
tive study and showed that the number of hands that needed
surgical excision (12.9% vs 70.7%) and the mean percentage of
burn wound area excised (4.4  13.1% compared to 52.0 
41.4%) was smaller than in the SOC group. No surgical
escharotomies were done compared to 9.7% in the SOC
group [6].
The panelists agree, that especially in contact burns in
children with a thinner epidermal layer Enzymatic Debride-
ment works well, after mechanical pre-treatment including
removal of keratin remnants.
Diabetic foot burns and patients with vascular occlusive
disease may suffer from developing further eschar and
deepening of their wounds and thus show disappointing
results [16]. The panelists agree that this cohort rarely benefits
from Enzymatic Debridement.
Hands, feet and extremities may serve as a well-chosen
region for the introduction of Enzymatic Debridement in a
burn center, but potential pit-falls and a special in-house
debridement treatment algorithm should be obeyed [8].
b. Face
13 ED is highly recommended for facial burns. [12/12]
Due to its unique anatomy in line with high demands on
preservation of dermis due to the functional and aesthetic
benefits, Enzymatic Debridement shows its strengths of
selective eschar removal in the face.
Schulz et al. evaluated the application of Enzymatic
Debridement for deep facial burns and compared it to SOC.
They showed that Enzymatic Debridement significantly
reduced time to complete wound closure after admission
(19.85 days versus 42.23 days, p = 0.002). The number of
procedures to complete debridement was significantly lower
in the enzymatic debridement group (1.00 versus 1.77, p =
0.003). Wounds undergoing autografting of any size were
significantly reduced by Enzymatic Debridement (15% versus
77%, p = 0.002). Scar quality after Enzymatic Debridement
was superior compared to surgical debridement after 12
months regarding pigmentation (p = 0.016), thickness (p =
0.16), relief (p = 0.10), pliability (p = 0.01), surface area (p =
0.004), stiffness (p = 0.023), thickness (0.011) and scar
irregularity (p = 0.011). In regard to erythema and melanin,
viscoelasticity and pliability, trans-epidermal water loss
or laser tissue oxygen saturation, hemoglobin level and
microcirculation no significant differences for treated
and untreated skin in the Enzymatic Debridement group
were found [10].
We find it important to point out that the safe application of
Enzymatic Debridement in the face requires special prepara-
tions of the sensory organs to protect them from contact with
the enzyme. The panelists agree that application in the face
requires significant experience with Enzymatic Debridement
and this region should not be chosen by those only beginning
their Enzymatic Debridement treatment experience.
14 Orifices of the face require special protection measures to
prevent them from contact with product. [12/12]
15 Ophthalmological exam after facial burns is recommended
prior to and after ED treatment. [12/12]
c. other regions
16 ED is recommended for perineal and genital burns. [12/12]
In general, the literature on perineal and genital burns is
scarce and favors long-lasting conservative treatment path-
ways prior to surgery to promote spontaneous healing because
reconstruction does not always lead to satisfying results.
Enzymatic Debridement may allow earlier and more selective
debridement, which can improve the outcome [11].
As perineal and genital burns benefit from advanced
surgical skills in terms of treating concave and convex regions
in close proximity Enzymatic Debridement may reveal its
ability to preserve viable dermis and prevent injury to vital
structures by the surgeons knife.
3.3. Consensus statements on imaging
Accurate evaluation of the burn wound is an essential part of
goal-directed, individual burn treatment, which is a keystone
supporting the concept of Enzymatic Debridement. Imaging
modalities in burn treatment have been evaluated to quantify
the evaluation of the depth and extent of the burn. Laser
Doppler Imaging (LDI) is regarded as the superior imaging
modality compared to other techniques, e.g. thermal imaging
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or clinical assessment, in terms of diagnostic accuracy [22,23].
LDI allows differentiation between burns that will heal without
skin grafting and burns that undergo skin grafts after
Enzymatic Debridement.
17 LDI is a helpful tool for identification of regions that
undergo ED. [12/12]
LDI is recommended in addition to clinical evaluation of
burn depth and aims to predict healing of the burn wound
within 21 days. It should be used after 48 h as blue scans on
early LDI are not helpful. [2426]. Seven out of 12 centers
use LDI systems, and 5 out of 7 have experience in LDI use
in the context of Enzymatic Debridement. LDI is regarded
as useful to predict regions which benefit from early
grafting after Enzymatic Debridement. The panelists agree
that LDI is the imaging tool of choice to be integrated
into the selective, individualized concept of Enzymatic
Debridement.
18 At the moment there is no evidence to support LDI after ED.
[11/12]
Currently there is no evidence that LDI is a helpful tool for
wound bed assessment after Enzymatic Debridement. Three
panelists have basic experience in the use of LDI after
Enzymatic Debridement, without a clear recommendation
for its application. Based on their experience, LDI is not reliable
after Enzymatic Debridement, as there is no correlation
between scan image and a clinical consequence.
3.4. Consensus statements on pain management and
anesthesia
Enzymatic Debridement is a selective, dermis-preserving
concept for eschar removal. Underestimation of its invasive-
ness may lead to inappropriate anesthesia and even for the
need for rescue analgesia [27]. Enzymatic Debridement is a
painful procedure and requires sufficient analgesia and/or
anesthesia [4,27]:
19 Regional anesthesia is recommended for ED of the isolated
(upper/lower) burnt extremity. [12/12]
20 Local anesthesia for ED is useful in minor burns. [12/12]
Four out of 12 panelists report experience with local
anesthesia, and all panelists have experience with regional
anesthesia. During the first consensus process in 2017, only
7 out of 12 panelist agreed to the use of regional anesthesia
[3]. For regional anesthesia use of catheter therapy or a single
shot with long-lasting locally acting anesthetic drugs is
preferred in view of safety issues and pain profile of
Enzymatic Debridement. Analgosedation is preferable over
general anesthesia.
Depending on the treated TBSA and patient conditions,
Enzymatic Debridement requires minimum monitoring
standards during treatment independent of anesthesia tech-
nique (i.v. line, pulse oximetry, access to monitoring, physician
on call)
3.5. Consensus statements on ED for large surface
treatment
21 Sequential ED procedures for larger TBSA are possible with
up to 15% TBSA per session. [12/12]
22 ED of more than 15% BSA/session requires adequate
monitoring and hemodynamic support and is considered
as an off-label use. [12/12]
Enzymatic Debridement for eschar removal is formally
limited to 15% treated TBSA per application by regulation
issues and approval. Principal advantages of the technique
have raised the idea of treating >15% TBSA per application
session. 5 out of 12 panelists have experience with more than
15% TBSA treatment per session. The panelists agree that
Enzymatic Debridement of large surfaces may produce
increased surface water loss and requires adapted resuscita-
tion/ volume management.
Scheduling a sequential ED procedure requires a stable
patient without an increased bleeding tendency. There are
concerns among the panelists in respect to a maximum of one
application session/day, analogous with a single surgical
procedure per day in SOC.
Currently there is no appropriate evidence to support the
use of Enzymatic Debridement for larger TBSA of > 15%. In
addition, there is a lack of evidence on the systemic response/
reduction of systemic response and on early large surface use
as a sub-entity.
3.6. Consensus statement on timing of application
Due to pre-soaking as a preparative dressing to ED, timing is
very flexible except for “immediate” ED to prevent BICS (see
also statement 1). Generally, there is no regulatory or clinical
contraindication for late application, e.g. in case of late
transfer to the burn center. Wounds should be carefully
selected to provide all requirements for Enzymatic Debride-
ment, including rehydration of the eschar by prolonged
presoaking and total removal of any external ointments,
which might interfere with the enzyme. Late application >72 h
from injury has not been addressed in the literature frequent-
ly, as the majority of clinical trial experience is from patients
treated within 72 h from injury [1].
23 Late Application (>72 h from injury) is possible in selected
wounds after appropriate prolonged presoaking. [12/12]
3.7. Consensus statements on preparation and application
Protection of the burn team is mandatory for the application of
Enzymatic Debridement for eschar removal, and has to include
protection measures analogous to a surgical procedure (e.g.
protective glasses).
The panelists are aware of 2 cases of severe allergic reaction
potentially related to the application of the product. This rare
event has to be considered prior to and during treatment, and
immediate abortion of the therapy by removal of the product
should be considered accompanied by appropriate therapy.
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24 Coagulopathy has to be treated prior to ED. [12/12]
Enzymatic Debridement is a powerful tool and has been
developed and validated to be more selective compared to the
SOC. In view of this power, it must be clearly emphasized, that
peri-procedural bleeding will occur and activity of the
coagulation system is essential — as it is for surgical burn
wound excision. As severely burnt patients may suffer from
coagulopathies in about 40% [28], these have to be treated prior
to Enzymatic Debridement. This is even more important when
large surfaces are treated in one session. There is one case
report in the literature, that describes a potential interaction
between Bromelain and hemostasis, as after intervention
close to the time of application a coagulation disorder occurred
[28]. The panelists have not experienced any comparable case
yet, but attention should be raised to peri-procedurally
checking the coagulation and quickly responding in case of
any coagulopathy.
25 Hydrogel dressings can be used as an effective moisturizer
for dry eschar to improve pre-soaking. [12/12]
Hydrogel based dressings with an antiseptic active agent
are regarded as effective dressing to improve the moistur-
izing process during pre-soaking. Due to approval regu-
lations and sourcing strategies, local, regional, and
international variations in the availability of rinsing
solutions and hydrogels with antiseptic activity exist and
may indirectly influence the results of treatment. In a
recent study, Schulz et al. addressed various agents and
their capability to inhibit enzymatic debridement activity in
vitro. Based on this study, polyhexanide-containing agents
are recommended to rinse and pre-soak burn wounds prior
to Enzymatic Debridement [29]. Experimentally, the au-
thors found a partial inhibition of enzymatic activity at the
distinct pH values of 3 and 11 [29].
26 Pre-Soaking can be scheduled overnight to synchronize the
ED application with the day shift team. [12/12]
The statements include a deviation from published and
standardized protocols, as pre-soaking is recommended for a
least 2 h. Nevertheless, the panelists agree that logistical
disadvantages may prevent implementation, and regard
prolonged soaking as a helpful strategy. In addition, the
panelists agree that prolonged post-soaking could be benefi-
cial to reduce the amounts of Enzymatic Debridement
remnants with potential impact on pseudoeschar.
27 Pretreatment with silver sulfadiazine or betadine should be
avoided. [12/12]
There is recent evidence from in vitro studies, that
pretreatment of burn wounds with agents containing silver
and copper should be avoided due to interference with
enzymatic activity [29].
28 Persistent dry eschar after pre-soaking benefits from
superficial surgical debridement prior to ED. [12/12]
Pre-treatment is necessary as ED does not penetrate
keratin/ epidermis and dry eschar down to moist eschar.
Superficial, mechanical pretreatment with curettes etc. is
recommended if Enzymatic Debridement is chosen for
selected eschar removal, but crusty, dry or epidermolytic
eschar tissue prevents sufficient penetration of the enzyme.
29 Shortening of the application time of the product <4 h
cannot be recommended. [11/12]
All panelists have experience and success in applying the
product for 4 h (or more because of logistical reasons), which is
the primary method in all published studies.
There is recent experimental evidence, that macrophage
activity during the inflammatory response after application of
Enzymatic Debridement results in protection of viable cells
and leads to inactivation of the enzyme after 4 h [30]. There was
not unanimous consensus on the statement, as one panelist
has experience with shorter application. Experience is only
limited to intermediate dermal burns, where durations of 2 h
seem to be sufficient. No experience on shorter application
phases for deep dermal or full thickness burns exist.
3.8. Consensus statements on post-interventional wound
management
The panelists agree, that post-Enzymatic Debridement wound
bed appearance and bleeding patterns are essential in the
evaluation and deciding the ideal treatment pathway after
Enzymatic Debridement. In general, after Enzymatic Debride-
ment, a decision should be made whether to follow an early
coverage pathway with grafting techniques or a conservative
pathway with prolonged observation time compared to regular
burn wounds.
Assessment of the wound bed color, bleeding patterns and
3D morphology is one of the most essential but also
demanding tasks during the implementation process for
Enzymatic Debridement.
30 Immediate post-ED wound bed color, bleeding patterns and
3D morphology should be assessed by an experienced burn
surgeon. [12/12]
The evaluation of the post-Enzymatic Debridement wound
bed is one of the most decisive steps in successful and
sustainable application of Enzymatic Debridement, and has to
consider the wound bed color and the bleeding pattern of the
whole treated area. Schematic drawings and photography of
both wound bed color and the bleeding pattern are essential, to
document the treatment results, especially in a large team.
This issue has been addressed in detail in the first European
Consensus Publication on Enzymatic Debridement [3].
31 A management plan with regard to further treatment
modalities should be directly defined after ED by an
experienced burn surgeon. [12/12]
Based on the wound bed color and the bleeding pattern of
the whole treated area, an individual management plan
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should be addressed, either to put the area(s) on a 1. Early
grafting or 2. Secondary healing pathway. Inordertoreducefurther
bleeding and donor sites for skin grafting, each treated area
benefits from an individual management plan. Further issues
include minimally invasive techniques for secondary debride-
ment immediately prior to skin grafting or (e.g. Hydrosurgery),
and concepts to keep the secondary wound healing process in
areas without skin grafting optimal (e.g. moisture). Further
pseudoeschar, which is characteristic for Enzymatic Debride-
ment, isbelievedtobepartofthehealingprocessand not a sign of
therapeutic failure. When pseudoeschar has been finally estab-
lished, re-evaluation of the wound bed in view of grafting vs.
secondary healing is technically impossible. This issue has been
also addressed in further detail in the first European Consensus
Publication on Enzymatic Debridement [3].
32 Membrane dressings and allografts can be applied after
wet-to-dry phase in wounds that are expected to heal
without autografting. [12/12]
There is evidence from the literature that membrane
dressings (e.g. Biobrane1, Suprathel1) are useful after Enzy-
matic Debridment in wounds that are not assessed and
scheduled for grafting [31]. The panelists agree that a decisive
and individualized post-interventional wound management is
an essential part of the concept and the key to success of
Enzymatic Debridement. Post interventional management is
strictly influenced by the individual availability of antiseptic
solutions and specific wound dressings, but some basic issues
should be considered in general. In a recent study Di Lonardo
et al. analyzed the effect of Enzymatic Debridement on mid-
deep partial thickness wounds, and observed that partially
damaged dermis was always spared by the enzymatic activity.
This dermis showed some "homogenization" characteristics,
had few vital skin adnexal structures in it, and therefore looked
very similar to the scaffold of dermal matrices currently
available on the market [13].
33 Allografts can be applied temporarily in wounds that are
not expected to heal spontaneously after ED prior to
autografting. [12/12]
Allograft represents a nearly ubiquitous available wound
dressing, which involves all relevant characteristics for an
appropriate wound dressing after Enzymatic Debridement if
not expected to heal spontaneously. Nevertheless, regulatory
limitations, general availability and costs may be an issue.
34 Indication for administration of antibiotics is equivalent to
surgical eschar removal.[12/12]
Burn wounds provide an ideal platform for bacterial
proliferation and a point of entry into the bloodstream,
mostly due to epithelial barrier loss and temporary immu-
nosuppression which predispose burn patients to infections.
Indication for administration of antibiotics during Enzymatic
Debridement for eschar removal should be regarded as
equivalent to SOC.
A meta-analysis of several studies on systemic, periopera-
tive prophylaxis (2 weeks) revealed a positive effect of
prophylactic antibiotic therapy, but limited validity due to
the low methodological quality of included studies and limited
comparability [32]. Early colonization by Pseudomonas aerugi-
nosa was even more common in the prophylaxis group than
the non-prophylaxis group. A recent Cochrane review con-
cluded that the benefits of prophylaxis in preventing burn
wound infections was still unclear [33]. In a systematic review,
antimicrobial prophylaxis was shown to be useful in patients
with severe burns receiving mechanical ventilation (Grade 2B)
[34]. As a result, prophylaxis cannot be recommended based on
the recent literature without restrictions, in relation to side
effects and costs of antibiotic therapy [32,35].
In contrast, peri-interventional and perioperative therapy
is chosen in surgery of the burn wound to reduce bacterial
load and bacteremia and associated increased graft infection
rates. It is recommended to administer a single shot, which
can be extended up to 48 h postoperatively. It can be
prolonged, if surgical debridement, resection and decontam-
ination is limited. Nevertheless, the evidence still is limited
[36]. In patients with minor burns and perioperative therapy
with a cephalosporin, a lower incidence of donor site
infection was shown, but without effects on the burn site
[37]. In a systematic review, perioperative therapy during
resection of devitalized tissue is of no benefit in most burn
patients (Grade 2B); however, there was not sufficient
evidence to make a recommendation for patients with
extensive burns. Antibiotic prophylaxis may also be effective
in preventing split-thickness skin graft infections in selected
procedures (Grade 2B) [34].
3.9. Consensus statements on autologous skin grafting
The panelists agree that grafting after Enzymatic Debridement
remains one of the most challenging issues on decision-
making in order to balance between the selective concept of
Enzymatic Debridement to reduce the rate of blood loss and
removal of healthy tissue and the clinical needs to prevent
patients from delayed, inappropriate burn wound healing and
associated reduced functional outcome. In future, it still
requires an open discussion and individual experience. Even
based on the huge, summarized experience of the panelists, no
conclusive statements are possible, as the decision to indicate
autologous skin transplantation is dependent on several
patient individual factors. These factors include the post-
interventional-bleeding pattern of different treated areas, 3D
wound bed morphology, time to heal and regions of interest.
Until now, no evidence supports a distinct time point for
transplantation dependent on the depth and bleeding pattern,
which has been shown to be superior. The panelists intended
to guide the applicants in the decision-making process on
autologous skin transplantation as follows:
35 In case of full thickness burns after ED, autologous skin
grafting should be delayed for at least 2 days. [12/12]
In order to gain back cellular wound bed integrity and to
limit secretion and local bleeding after the procedure,
autologous skin grafting should be postponed for at least
two days to improve graft take rates. The decision is based on
the post-interventional bleeding pattern.
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36 Deep dermal burn wounds may benefit from early auto-
grafting. [12/12]
Early closure should be addressed, when fat layers and
thrombosed veins are visible after Enzymatic Debridement. In
these deep dermal wounds, additional eschar removal may be
addressed by minimal-invasive surgical techniques, e.g.
Hydrosurgery. The post-interventional bleeding pattern may
guide the surgical decision.
37 Autologous skin grafting should be considered after 21 days
if there is no significant progress in epithelization. [11/12]
In superficial to mid-dermal/deep-dermal wounds with an
appropriate LDI and bleeding-pattern suggesting secondary
healing, skin transplantation is not primarily scheduled, as
healing without transplantation is regarded to have a superior
outcome in these patients and pseudoeschar as a typical
product of the treatment may not allow later interpretation
[1,10]. Nevertheless, if secondary healing is significantly
delayed, procrastination in regard to autologous skin trans-
plantation may result in unstable scarring and functional
limitations.
In order to address this most debatable issue, in the 1st
consensus meeting on Enzymatic Debridement in burns, with
a consensus of 7 out of 10 panelists, it was stated that
“Autologous skin grafting is advisable at latest after 21 days if
there is no progress in epithelization.” [3]. In the 2nd consensus
meeting, which is based on a significantly higher experience of
cases treated with Enzymatic Debridement, this very state-
ment was rephrased  resulting in a consensus of 11 out of 12
(91.6%).
Keratinocyte-Suspension may support re-epithelization
and is less invasive compared to skin grafts. Two centers
have experience with Keratinocyte-Suspensions as an adjunct
to improve secondary healing, but the panelists agree that
further evaluation is required before a general recommenda-
tion is justified.
3.10. Consensus statements on outcome, scars and revision
management
38 Scar treatment and prevention of hypertrophic scars is
performed according to established standard protocols in
burn care (Compression garments, silicon and abstention
from UV-radiation). [12/12]
After Enzymatic Debridement there is a risk profiling for
delayed wound healing in burn wounds: all wounds that take >
than 3 weeksfor healing or skin graftedwounds afterEnzymatic
Debridement benefit from full anti-scar therapy for at least one
year. This consists of pressure garments, silicone garments or
sheets, inlays, moisturizers, physical therapy, sometimes
additional surgery). Further evidence on the mid- to long-term
outcome on these issues is not available yet.
39 Prolonged conservative treatment after ED may result in
unstable scarring with intensive wound care, and regular
reconsideration should be given for autografting. [12/12]
Prolonged conservative treatment after day 21 is a very
demanding option, as the risk for unfavorable scarring after
delayed healing maybe higher compared to autologous skin
grafting.
3.11. Consensus statements on cost-effectiveness
40 ED may help to reduce usage of resources (blood products,
surgery, OR room capacity, human resources). [12/12]
Enzymatic Debridement is a useful tool, which may help to
reduce classical resources for surgical burn eschar removal.
While surgical eschar removal is traditionally applied in the
operationroom, EnzymaticDebridementisdoneat the burnICU
or a regular burn ward. The surgeon is not required during the
whole therapy of Enzymatic Debridement. Only secondary skin
transplantation has to be scheduled in the operation room, but
with reduced surface area [14,15]. In addition, the selective
approach of Enzymatic Debridement may help to reduce blood
product resource as demonstrated before [1]. In view of various
health care systems of the participating panelist and in general,
there must be chosen an individual approach to analyze and
communicate cost-effectiveness, which is dependent on
individual reimbursement of Enzymatic Debridement, chan-
neled by the national health care system.
3.12. Consensus statements on the patients perspective
after ED
41 Data on the patients experience on ED are rare and future
research on patient experience is needed. [12/12]
Patient reported outcome measures (PROMSs) are under
reported in the current literature. Patients report significant
pain during and after ED. Therefore adequate analgesia is
essential. Pain is the only outcome parameter and only
addressed in one paper [4]. Patients reported scar assessment
is addressed in most of the recent articles.
3.13. Consensus Statements on Logistic aspects for
implementation and Training strategies/learning curve
42 ED can be performed in the operating theatre, intensive
care unit or regular ward dependent on the TBSA treated
and the anesthesia regimen. [12/12]
43 ED is a specialist procedure that requires specific training,
adaption to infrastructure as well as multi-professional
involvement. [12/12]
Implementation of ED requires individual SOPs, adapted to
house lists (dressings, external ointments, active dressing’s
gauze) and logistics. A steep learning curve may necessitate
further training. It is imperative to create enthusiasm for this
method of debridement which often requires more effort from
the surgeons, the nurses and the anesthesiologists/intensive
care doctors who are in charge of pain management and
resuscitation of the patient
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A relevant learning curve is obvious, but logistics issues
may require even more attention.
3.14. Areas of future research and future issues
The panelists agreed that there are several relevant issues,
which should be addressed in future, both in clinical and
experimental research on Enzymatic Debridement. These
issues in particular include the patients perspective, systemic
inflammatory response and systemic effect of Bromelain after
Enzymatic Debridement. In addition, the panelists recom-
mend establishing a registry/database of all patients treated
with Enzymatic Debridement for further evaluation of this
promising technique. A biennale Consensus Workshop is
recommended to be held due to its ongoing development.
4. Discussion
After its approval in Europe in 2013, Enzymatic Debridement
with Nexobrid1 as an additional tool for a more individualized,
selected and less invasive burn eschar removal has gained
significantly increasing attention and application rates among
burn surgeons worldwide during the last 5 years [6,31]. The
summarized experience of 1232 treated patients reflects the
significance of the provided user-orientated recommenda-
tions for a successful implementation and application of
Enzymatic Debridement for eschar removal. Compared to the
first summarized experience of the panelist with approxi-
mately 500 patients additional 700 patients have been treated
as the basis of this consensus document. [3].
Forty-three statements were formulated, addressing the
topics: indications, pain management and anesthesia, large
surface indication, timing of application for various indications,
preparation and application, post-interventional wound man-
agement, skin grafting, outcome, scar and revision manage-
ment, cost-effectiveness, patients perspective, logistic aspects
and training strategies. The degree of consensus was high, with
consensus in 42 out of 43 statements (97.7%), while no
consensus was achieved on the role of outpatient treatment/
ED as day cases in minor burns in experienced burn centers. A
classification with regard to timing of application for Enzymatic
Debridement was introduced, with immediate/ very early (12
h), early (1272 h) or delayed (>72 h) treatment.
The potential of outpatient treatment remains a relatively
new controversial issue, as it principally raises further benefits
of the concept. In contrast, LDI and skin grafting remain
controversy topics, but with further clarifications and recom-
mendations, and a higher degree of consensus, than in the first
European Consensus Meeting in 2017 [3].
Enzymatic Debridement may show its advantages in
severely burned patients, as it allows very early, less-traumatic
removal of necrotic tissue even in patients whose overall
clinical conditions would mandate delaying traditional surgi-
cal eschar removal.
The increasing experience in the application of Enzymatic
Debridement also reveals some limitations, which are useful
to discuss to improve the success rates:
Berner et al. published their experience of treating burns
in patients with established diabetic foot disease in a case
series. The authors described that all of these patients
developed further eschar and deepening of their wounds a
few days after Enzymatic Debridement, and underwent
further surgery and skin grafting. Based on their limited
experience they recommend avoiding Enzymatic Debride-
ment in patients with diabetic foot wounds, as the special
issues of microangiopathy seem to counteract this technique
and the bleeding patterns [16].
Until now, there is no evidence that supports Enzymatic
Debridement in chemical burns with potential interaction and
inactivation. In addition, high voltage injuries with potential
deep muscle damage and increased compartment pressures
should not be treated with Enzymatic Debridement for
immediate eschar removal and compartment release, as the
enzyme limits its activity to the eschar and cannot release
muscular compartments. Additionally, scald burns do not
show comparable results after Enzymatic Debridement com-
pared to flame burns, which is the reason not to recommend
the technique in the early phase for scald burns and limited
recommendation in general. The panelists agree that Enzy-
matic Debridement of large surfaces may be feasible, but may
produce increased surface water loss and adapted resuscita-
tion/ volume management. Furthermore, the “ideal patient”
for large surface indications has to be defined, and the
systemic effect of Bromelain and early eschar removal in
the context of Enzymatic Debridement should be evaluated.
Several areas for treatment have been demonstrated to
work well, e.g. hands [49] as well as burns to the face [10] and
genitals [11], with most published studies and patients on
hand burns. Fischer et al. demonstrated the feasibility and
safety of Enzymatic Debridement for the prevention of
operative escharotomy in circumferential deep burns of the
distal upper extremity [12]. These findings are in line with and
strengthened by the panelists’ experience. It should be applied
as early as possible (“very early”), and should not be delayed by
presoaking. LDI has been evaluated and identified as an
important imaging device, which is linked to the concept of
selective Enzymatic Debridement and is useful to predict
regions which benefit from early grafting after Enzymatic
Debridement [2426].
The panel conducted an intensive debate on the use of
Enzymatic Debridement in case of limited operation room
capacity in the setting of a mass casualty. No statement was
regarded as possible for consensus. The panelists agree that
early Enzymatic Debridement in mass causalities may cause
further issues, as patients may undergo further transplanta-
tion and resources such as blood products, though Rosenberg
et al. have shown reduced need for blood products after
Enzymatic Debridement in general [1].
4.1. Limitations
Although the present consensus paper refers to the summa-
rized experience of 1232 patient cases of the panelist and is in
line with the present evidence on Enzymatic Debridement
including randomized-controlled trials (LoE 1) to case reports
(LoE4), the present consensus reflects expert opinions (LoE5).
Not all recommendations can be supported by the available
literature, as this is often limited in view of practical clinical
issues. In addition, not all relevant issues on Enzymatic
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Debridement could be addressed or re-evaluated from the first
panel meeting, as the available panel time was limited.
4.2. Conclusion
The updated guidelines in this publication represent further
refinements on the indication, application and post-inter-
ventional management for the use of Enzymatic Debride-
ment. The published statements contain detailed, user-
orientated recommendations aiming to align current and
future users and prevent unnecessary pitfalls for the
successful implementation of this promising technique.
The present consensus publication aims to manage the
balancing act between evidence and user-orientated recom-
mendations base on the methodology of the panel meeting.
We believe that future, regular readjustments and fine-
tuning of these recommendations should be performed to
define relevant study topics, and to adopt further knowledge
and evidence.
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